What medication clears up plaque psoriasis and is recommended by most dermatologists, but also can’t be defeated or understood, has cropped up periodically throughout human history and is unaffecte | ...

Dual therapy with a GLP-1 receptor agonist plus ixekizumab demonstrates long-term benefits in psoriatic disease activity, ...

The FDA granted the approval following findings from the pivotal POETYK PsA-I and POETYK PsA-II Phase III studies.

Regulatory expansion positions deucravacitinib 6 mg once daily as a first-in-class oral TYK2 option for active PsA, complementing its prior plaque psoriasis indication. POETYK PsA-1 showed significant ...

Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the landmark TOGETHER-PsO open-label Phase 3b clinical trial evaluating the concomitant use of Taltz (ixekizumab) and ...

In clinical trials, more than half of all patients treated with deucravacitinib achieved at least 20% improvement in American College of Rheumatology response criteria.

Sotyktu (deucravacitinib) for treatment of adults with active psoriatic arthritis (PsA). Sotyktu is an oral, selective ...

Can what you eat help calm psoriasis, a chronic inflammatory disease that affects the skin? It's identified by the development of thick, red patches with silvery scales, causing the area to itch or ...

Scott Gottlieb, MD, discusses the real-world outcomes of tildrakizumab for moderate to severe plaque psoriasis.

Risankizumab is effective through 2.5 years of treatment among patients with psoriasis, with most patients achieving rapid and sustained response.

FDA approval introduces first-in-class, once-daily oral TYK2 inhibition for active psoriatic arthritis, expanding deucravacitinib beyond its 2022 plaque psoriasis indication. POETYK PsA-1 and PsA-2 ...